PacBio moved to Neutral at JPMorgan after guidance cut
Seeking Alpha News (Mon, 22-Apr 8:50 AM ET)
TipRanks (Mon, 22-Apr 4:20 AM ET)
PacBio cut to Neutral at Goldman Sachs after guidance cut
Seeking Alpha News (Thu, 18-Apr 8:15 AM ET)
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY)
TipRanks (Thu, 18-Apr 7:20 AM ET)
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
PRNewswire (Tue, 16-Apr 8:05 AM ET)
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
PRNewswire (Wed, 27-Mar 8:00 AM ET)
PacBio Grants Equity Incentive Award to New Employee
PRNewswire (Fri, 22-Mar 4:30 PM ET)
PRNewswire (Tue, 12-Mar 9:05 AM ET)
PacBio to Present at Upcoming Investor Conferences
PRNewswire (Mon, 26-Feb 4:05 PM ET)
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
PRNewswire (Thu, 15-Feb 4:05 PM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of April 23, 2024, PACB stock price declined to $1.47 with 9,255,914 million shares trading.
PACB has a beta of 3.69, meaning it tends to be more sensitive to market movements. PACB has a correlation of 0.22 to the broad based SPY ETF.
PACB has a market cap of $393.14 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $58 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $867,000 and exceeded earnings estimates by $.01.
In the last 3 years, PACB stock traded as high as $36.36 and as low as $1.25.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): VTI, ARKK, VB, ARKG, VBR.
PACB has underperformed the market in the last year with a price return of -86.6% while the SPY ETF gained +24.3%. PACB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.6% and -57.4%, respectively, while the SPY returned +4.9% and -2.5%, respectively.
PACB support price is $1.46 and resistance is $1.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB stock will trade within this expected range on the day.